

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug delivery</b>			
Atherosclerotic plaque-homing peptide (LyP-1) for plaque imaging and targeted drug delivery	<p>The cyclic nonapeptide LyP-1 could be a useful imaging agent or delivery vehicle for compounds to treat atherosclerosis. In mouse models of atherosclerosis, LyP-1 conjugated to a fluorophore, a PET imaging agent or an MRI agent preferentially accumulated in atherosclerotic plaques compared with a similarly conjugated inactive control peptide. Ongoing work includes using LyP-1 to deliver undisclosed therapeutics to atherosclerotic plaques.</p> <p><b>SciBX 4(16); doi:10.1038/scibx.2011.466</b> Published online April 21, 2011</p>	Patented by the Sanford-Burnham Medical Research Institute; available for licensing or partnering	<p>Hamzah, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online April 11, 2011; doi:10.1073/pnas.1104540108 <b>Contact:</b> Erkki Ruoslahti, Sanford-Burnham Medical Research Institute, La Jolla, Calif. e-mail: <a href="mailto:ruoslahti@sanfordburnham.org">ruoslahti@sanfordburnham.org</a></p>